AlphaMaven AlphaMaven
Lab testing group Intertek to back £10.6bn takeover by Swedish firm EQT
Back to News
AlphaMaven Alternative Investment News
Private Equity

Lab testing group Intertek to back £10.6bn takeover by Swedish firm EQT

theguardian
5 months ago
FTSE 100 business ‘minded to recommend’ £60-a-share tilt from company owned by billionaire Wallenberg familyThe laboratory testing company Intertek has become the latest FTSE 100 business to agree to a takeover, backing a £10.6bn approach from a private equity firm owned by Sweden’s billionaire Wallenberg family.After rebuffing three previous approaches, Intertek’s board said it was “minded to recommend” the £60-a-share tilt from the Swedish buyout firm EQT to shareholders, if there is a firm offer. Continue reading...

Read the full intelligence on AlphaMaven

Subscribe to unlock the AI-extracted Key Takeaways, the News Summary that synthesizes this story with related coverage, and the full alternative-investment intelligence platform — $99/mo, no contract, cancel anytime.

Start research — $99/mo Login

News Summary available

Subscribe to unlock the News Summary

Key Takeaways + full Summary on every story · $99/mo, no contract

Start research — $99/mo

Not a member yet?

Why AlphaMaven

The Alternative Investment
Intelligence Platform

Access nearly 1 million industry profiles in alternative investments — firms, funds, decision-makers and regulatory filings.

Start a free 7-day trial — card required, cancel anytime
Data · Intelligence · ROI
Company, fund & contact directory
Screener with filters & saved searches
Regulatory data — SEC, NFA, GLEIF, Form D
Manager-reported fund performance
11K+ members contributing data
Daily news with AI executive summaries
Data exports from your tracked list
Research guides, leaderboards & glossary
155,600+
Firms
543,500+
Decision-Makers
70,000+
Data Sources
Start your free 7-day trial

ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.

© 2026 Maven Data Group, Inc.